Back to Newsroom
Back to Newsroom

AdOM Advanced Optical Technologies Ltd. Announces the Launch of the Tear Film Imager (TFI) Device in the U.S.

Wednesday, March 10, 2021 10:45 AM
AdOM advanced optical technologies Ltd

LOD, ISRAEL / ACCESSWIRE / March 10, 2021 / AdOM Advanced Optical technologies Ltd., a clinical and commercial stage ophthalmic medical device company, announces the launch of the Tear Film Imager (TFI) device in the U.S.

The TFI is a non-invasive imaging device which is designed to simultaneously measure the muco-aqueous and lipid sublayers of the eye, at a dept resolution of nanometer level. It's use involves a brief 40 second exam per eye to provide a comprehensive assessment on the health of the tear film sublayers. The TFI device has the potential to play an important role in the evaluation and management of dry eye disease (DED). While other methods only indirectly measure some attributes of the tears and give little information about tear film characteristics in an undisturbed state, the TFI device can characterize the natural behavior of human tears while allowing the patient to blink naturally which is important in the management of DED.

AdOM participated in several studies including the 3D-WLT study and the 14-LV-001-RD study (Israel and Canada respectively) where both DED and normal subjects were tested. In these studies, the TFI prototype performed more than 1,000 measurements at a rate of up to 30 per day with no safety or operational issues. The studies also confirmed good precision and repeatability.

"AdOM is excited about a U.S. commercial launch of the Tear Film Imager. Our scientists used advances in hyperspectral technology to design this imaging device which generates measurements of the tear film inner layers", states John Abrams, MD, Ophthalmologist and President of AdOM.

"The company is now focused on commercializing the TFI device into the U.S. marketplace for selected customers and will begin with an emphasis on major academic medical centers and related industries who are seeking an instrument that can provide rapid, non-invasive measurements of the tear film sublayers."

AdOM is excited to present the TFI device at the upcoming OIS Dry eye innovation showcase on March 11th. Stan Miele, the chief business officer will provide an overview of the technology and its ability to assess tear film physiology.

Dry Eye Disease is caused by a combination of decreased tear production and/or increased tear film evaporation. It is considered a world-wide challenge due to an aging population, routine performance of LASIK (vision correction) surgeries, and the extensive use of contact lenses. Approximately 60% of secondary office visits are a result of dry eye. It is estimated that globally there are ~337 million people suffering from Dry Eye Disease and this represents a medical treatment market of over $4.5B USD.

About AdOM Advanced Optical Methods

AdOM is a development and commercial stage ophthalmic medical device company which uses hyperspectral technology to measure the dynamics of the tear film inner structures. Founded in 2008 and led by a team of scientists, AdOM's science driven approach led to the identification of advances in hyperspectral technology, and the use of this application in diseases of the eye. The TFI is the first AdOM device to be registered with the U.S. Food and Drug Administration (under its Class I exemption for this device type) and the company is focused on seeking regulatory authorization in other territories. For additional information about the company, please visit

AdOM Advanced Optical Technologies
Contact: Stan Miele (919-410-0504) / Raanan Gefen
[email protected] / [email protected]

SOURCE: AdOM advanced optical technologies Ltd:

Product Announcements
Back to newsroom
Back to Newsroom